Megyrina (Megestrol Acetate)

Megestrol acetate is a synthetic progestogen that activates intracellular progesterone receptors, leading to transcriptional changes that suppress tumor growth. It also exerts glucocorticoid‑like effects on the hypothalamus, decreasing catabolic pathways and stimulating appetite, which together address both tumor control and weight loss.

The dosage of Megyrina is individualized. A qualified prescriber determines the appropriate strength, frequency, and duration based on the patient’s clinical condition, response, and any concomitant therapies. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for megestrol acetate in pregnancy and lactation are limited, and the pregnancy category is listed as unknown. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and clinicians should discuss alternatives with pregnant or nursing patients.

To request Megyrina, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with agents such as dronabinol or mirtazapine, Megyrina offers both appetite stimulation and antineoplastic activity due to its progestogenic and glucocorticoid‑like properties. While other stimulants may lack hormonal effects, Megyrina can address tumor‑related pathways but may carry higher risks of hormonal side effects and thromboembolic events.

Megyrina tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Megyrina is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional. Dosing times may be adjusted to align with meals or other medications as advised by the prescriber.

The most serious adverse events associated with Megyrina include thromboembolic complications such as deep‑vein thrombosis or pulmonary embolism, and adrenal insufficiency that can occur if the drug is stopped abruptly. Patients should be monitored for signs of clotting, unexplained fatigue, or sudden hormonal changes.

Megyrina is contraindicated in individuals with known hypersensitivity to megestrol acetate, active thromboembolic disease, uncontrolled diabetes, or severe hypertension. Caution is also advised for patients with liver impairment or those taking medications that strongly interact with its metabolism.